PURPOSE: Human epidermal growth factor receptor type 3 (HER3) is a transmembrane receptor tyrosine kinase belonging to the HER (ErbB) receptor family. Membranous expression of HER3 is associated with trastuzumab resistance in breast cancer and the transition to androgen independence in prostate cancer. Imaging of HER3 expression in malignant tumors may provide important diagnostic information that can influence patient management. Affibody molecules with low picomolar affinity to HER3 were recently selected. The aim of this study was to investigate the feasibility of HER3 imaging using radiolabeled Affibody molecules. METHODS: A HER3-binding Affibody molecule, Z08699, with a HEHEHE-tag on N-terminus was labeled with (99m)Tc(CO)3 using an IsoLink kit. In vitro and in vivo binding specificity and the cellular processing of the labeled binder were evaluated. Biodistribution of (99m)Tc(CO)3-HEHEHE-Z08699 was studied over time in mice bearing HER3-expressing xenografts. RESULTS: HEHEHE-Z08699 was labeled with (99m)Tc(CO)3 with an isolated yield of >80 % and a purity of >99 %. Binding of (99m)Tc(CO)3-HEHEHE-Z08699 was specific to BT474 and MCF7 (breast cancer), and LS174T (colon cancer) cells. Cellular processing showed rapid binding and relatively quick internalization of the receptor/Affibody molecule complex (70 % of cell-associated radioactivity was internalized after 24 h). The tumor targeting was receptor mediated and the excretion was predominantly renal. Receptor-mediated uptake was also found in the liver, lung, stomach, intestine, and salivary glands. At 4 h pi, tumor-to-blood ratios were 7 ± 3 for BT474, and 6 ± 2 for LS174T xenografts. LS174T tumors were visualized by microSPECT 4 h pi. CONCLUSIONS: The results of this study suggest the feasibility of HER3-imaging in malignant tumors using Affibody molecules.
PURPOSE:Human epidermal growth factor receptor type 3 (HER3) is a transmembrane receptor tyrosine kinase belonging to the HER (ErbB) receptor family. Membranous expression of HER3 is associated with trastuzumab resistance in breast cancer and the transition to androgen independence in prostate cancer. Imaging of HER3 expression in malignant tumors may provide important diagnostic information that can influence patient management. Affibody molecules with low picomolar affinity to HER3 were recently selected. The aim of this study was to investigate the feasibility of HER3 imaging using radiolabeled Affibody molecules. METHODS: A HER3-binding Affibody molecule, Z08699, with a HEHEHE-tag on N-terminus was labeled with (99m)Tc(CO)3 using an IsoLink kit. In vitro and in vivo binding specificity and the cellular processing of the labeled binder were evaluated. Biodistribution of (99m)Tc(CO)3-HEHEHE-Z08699 was studied over time in mice bearing HER3-expressing xenografts. RESULTS: HEHEHE-Z08699 was labeled with (99m)Tc(CO)3 with an isolated yield of >80 % and a purity of >99 %. Binding of (99m)Tc(CO)3-HEHEHE-Z08699 was specific to BT474 and MCF7 (breast cancer), and LS174T (colon cancer) cells. Cellular processing showed rapid binding and relatively quick internalization of the receptor/Affibody molecule complex (70 % of cell-associated radioactivity was internalized after 24 h). The tumor targeting was receptor mediated and the excretion was predominantly renal. Receptor-mediated uptake was also found in the liver, lung, stomach, intestine, and salivary glands. At 4 h pi, tumor-to-blood ratios were 7 ± 3 for BT474, and 6 ± 2 for LS174T xenografts. LS174T tumors were visualized by microSPECT 4 h pi. CONCLUSIONS: The results of this study suggest the feasibility of HER3-imaging in malignant tumors using Affibody molecules.
Authors: Anna Orlova; Vladimir Tolmachev; Rikard Pehrson; Malin Lindborg; Thuy Tran; Mattias Sandström; Fredrik Y Nilsson; Anders Wennborg; Lars Abrahmsén; Joachim Feldwisch Journal: Cancer Res Date: 2007-03-01 Impact factor: 12.701
Authors: Vladimir Tolmachev; Zohreh Varasteh; Hadis Honarvar; Seyed Jalal Hosseinimehr; Olof Eriksson; Per Jonasson; Fredrik Y Frejd; Lars Abrahmsen; Anna Orlova Journal: J Nucl Med Date: 2014-01-09 Impact factor: 10.057
Authors: Richard P Baum; Vikas Prasad; Dirk Müller; Christiane Schuchardt; Anna Orlova; Anders Wennborg; Vladimir Tolmachev; Joachim Feldwisch Journal: J Nucl Med Date: 2010-05-19 Impact factor: 10.057
Authors: Nina Kronqvist; Magdalena Malm; Lovisa Göstring; Elin Gunneriusson; Martin Nilsson; Ingmarie Höidén Guthenberg; Lars Gedda; Fredrik Y Frejd; Stefan Ståhl; John Löfblom Journal: Protein Eng Des Sel Date: 2010-12-21 Impact factor: 1.650
Authors: Vladimir Tolmachev; Helena Wållberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-11 Impact factor: 9.236
Authors: Anna Orlova; Mikaela Magnusson; Tove L J Eriksson; Martin Nilsson; Barbro Larsson; Ingmarie Höidén-Guthenberg; Charles Widström; Jörgen Carlsson; Vladimir Tolmachev; Stefan Ståhl; Fredrik Y Nilsson Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Vladimir Tolmachev; Daniel Rosik; Helena Wållberg; Anna Sjöberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-17 Impact factor: 9.236
Authors: Carlos D Martins; Chiara Da Pieve; Thomas A Burley; Rhodri Smith; Daniela M Ciobota; Louis Allott; Kevin J Harrington; Wim J G Oyen; Graham Smith; Gabriela Kramer-Marek Journal: Clin Cancer Res Date: 2018-02-06 Impact factor: 12.531
Authors: John S Schardt; Jinan M Oubaid; Sonya C Williams; James L Howard; Chloe M Aloimonos; Michelle L Bookstaver; Tek N Lamichhane; Sonja Sokic; Mariya S Liyasova; Maura O'Neill; Thorkell Andresson; Arif Hussain; Stanley Lipkowitz; Steven M Jay Journal: Mol Pharm Date: 2017-03-08 Impact factor: 4.939
Authors: Sara S Rinne; Wen Yin; Anna Mestre Borras; Ayman Abouzayed; Charles Dahlsson Leitao; Anzhelika Vorobyeva; John Löfblom; Stefan Ståhl; Anna Orlova; Torbjörn Gräslund Journal: Biomedicines Date: 2022-05-31
Authors: Maria Rosestedt; Ken G Andersson; Bogdan Mitran; Vladimir Tolmachev; John Löfblom; Anna Orlova; Stefan Ståhl Journal: Sci Rep Date: 2015-10-19 Impact factor: 4.379